+8 - Solvay

More documents

Recommendations

Info

Activities Group sales 2006 = EUR 9 399 million 3640 3120 2600 2080 1560 1040 520 0 1 745 2 601 2 270 2 433 2 998 2 785 3 093 3 800 3 507 Pharmaceuticals Chemicals Plastics Group REBIT 2006 = EUR 1 099 million [Including “Corporate & Business Support” : EUR -76 million] 480 420 360 300 240 180 120 60 0 236 302 451 180 285 315 374 389 Pharmaceuticals Chemicals Plastics Group employees at January 1, 2007: 29 258 people A global presence Group sales 2006 = EUR 9 399 million 34 % 8 % 2 % 56 % Customer markets Group sales 2006 = EUR 9 399 million g Europe 50 % European Union (25) 6 % Other European countries g Asia-Pacifc g The Americas 26 % Nafta 8 % Mercosur g Rest of world Human health 30 % Automobile industry 12 % Construction and architecture 11 % Chemical industry 10 % Glass industry 6 % Water and the environment 5 % Electricity and electronics 4 % 6 517 2 142 409 48 Nafta 26 % Mercosul 8 % 20 551 g 2004 g 2005 g 2006 g 2004 g 2005 g 2006 Les Amériques 34 % Sales by Sector in 2006 40 % 35 % 27 % 32 % 28 % REBIT* by Sector in 2006 [*Excluding “Corporate & Business Support” : -76 millions EUR] 8 889 Group employees at January 1, 2007: 29 258 people 1 590 8 691 38 % Employees by Sector in 2006 10 088 g Europe 19 671 European Union (25) 880 Other European countries g Asia-Pacific g Reste The Americas du monde 3 4 % 967 Nafta 1 550 Mercosur g 1 531 Rest of world Europe 55 % g Pharmaceuticals g Chemicals g Plastics g Pharmaceuticals g Chemicals g Plastics g Pharmaceuticals g Chemicals g Plastics g Corporate Union Européenne (25) 50 % Autres pays européens 5 % Paper 4 % Consumer goods 3 % Asie Detergents, cleaning and Pacifique hygiene product 8 % 3 % Packaging 3 % Human and animal food processing 1 % Other industries 8 %
Highlights January Mississippi Polymer Technologies Solvay boosts high-performance-polymer portfolio by acquiring Mississippi Polymer Technologies (USA). February EPicErol Solvay builds new epichlorohydrin plant at Tavaux (France) to meet growing demand, using a new production process based on natural glycerine (EPICEROL ). March AndrogEl ® Solvay Pharmaceuticals signs new agreement to secure maximum global expansion of ANDROGEL ® . April renolit Solvay completes sale of Industrial Foils activities to Renolit (Germany). May dHHS Solvay Pharmaceuticals awarded USD 298 million subsidy from the US Department of Health and Human Services to develop flu vaccines and design a manufacturing unit. gharda Solvay concludes acquisition of plastics division of Gharda to expand in high-performance polymers in India. Exeltium Solvay co-founds Exeltium, a grouping of electro-intensive industries in France – a creative solution for long-term control of energy costs. June PolyMiST ® Solvay decides to produce POLYMIST ® specialty polymers at Changshu (China). July Fenofibrate Abbott and AstraZeneca sign agreement to develop for the USA a new combined total lipids regulation therapy incorporating a fenofibrate. Egeplast Egeplast (Germany) acquires innovative Solvay technology for fully recyclable high-pressure pipes. Solvicore Solvay and Umicore launch SolviCore (Germany) to develop and produce membrane electrode assemblies (MEA) for core fuel cell applications. August Hydrogen fluoride Solvay sets up partnership to produce hydrogen fluoride, an essential component of many fluorinated products, in the Shanghai (China) region. Solvay indupa Solvay Indupa announces ambitious plan to expand and upgrade vinyls production in Brazil. Pangaea Ventures fund ii Solvay participates in Pangaea Ventures Fund II (Canada), investing in leading-edge materials for information and communication technologies (ICT). September e-billing Solvay pioneers electronic billing in Europe. BASF and dow BASF and Dow begin construction at Antwerp (Belgium) of a propylene oxide unit using Solvay-produced hydrogen peroxide. october bifeprunox Solvay Pharmaceuticals and Wyeth announce they have filed for US approval of their new bifeprunox schizophrenia drug. Ultra-polymer Solvay expands and upgrades its ultra-polymer plant at Panoli (India). november nAnoVin SolVin launches its NANOVIN vinyl nanocomposite “smart material”. PErESTAnE ® Solvay launches environmentally-friendly PERESTANE ® biocide against nosocomial diseases. december SlV319 SLV319, the obesity drug Solvay is developing with Bristol-Myers Squibb, moves forward in phase II clinical trials. bifeprunox USA Food and Drug Administration registers the bifeprunox filing submitted in October 2006. Solvay innovation Trophy Solvay Innovation Trophy awarded to the eight most innovative of 96 competing projects. 2006 Highlights Solvay Global Annual Report 2006
Page 1 and 2: Moving forward together Growth, Com
Page 3: Key figures - Solvay Group Financia
Page 7 and 8: At the end of a rigorous selection
Page 9 and 10: a Passion for Progress ® our Visio
Page 11 and 12: materials at Shanghai, a new micron
Page 13 and 14: Progress by Sector 1. Sales by Sect
Page 15 and 16: Expenditure for the future: Capital
Page 17 and 18: no changes in accounting principles
Page 19 and 20: Specialties Solvay Specialties from
Page 21 and 22: Pharmaceuticals Sector Building the
Page 23 and 24: Fenofibrates In fenofibrates, Solva
Page 25 and 26: Flagship products in 2006 Pharmaceu
Page 27 and 28: Bruno Loillier Senior biology lab t
Page 29 and 30: Valérie Lepais Senior chemistry la
Page 31 and 32: Pharmaceuticals Sector Therapeutic
Page 33 and 34: Earning the right to growth Eric Ar
Page 35 and 36: Strategy The rewards of partnership
Page 37 and 38: The “Electrochemistry and Fluorin
Page 39 and 40: Chemicals Sector Jean-Paul Attencou
Page 41 and 42: The “Organic” cluster: Molecula
Page 43 and 44: Building on our strong points, expa
Page 45 and 46: Strategy Innovation Innovation was
Page 47 and 48: Two acquisitions were also complete
Page 49 and 50: In a highly competitive European si
Page 51 and 52: Simone Di Paolo Pilot Plants Techni
Page 53 and 54: New Business Development NBD strate
Page 55 and 56:
at low cost and on a continuous bas
Page 57 and 58:
Jan-Eric Zandbergen (Olst/The Nethe
Page 59 and 60:
- Career management The career deve
Page 61 and 62:
Sustainable Development Primary thr
Page 63 and 64:
took the Innovation Trophy 2006 in
Page 65 and 66:
Financial Statements The following
Page 67 and 68:
Consolidated balance sheet EUR Mill
Page 69 and 70:
Currency translation differences Th
Page 71 and 72:
The main exchange rates used are :
Page 73 and 74:
- Cash and cash equivalents The cas
Page 75 and 76:
Information per primary segment for
Page 77 and 78:
(6) Other operating gains and losse
Page 79 and 80:
The tax charge breaks down as follo
Page 81 and 82:
(13) Income from investments Income
Page 83 and 84:
Acquisitions of subsidiaries EUR Mi
Page 85 and 86:
The 3-year vesting period is follow
Page 87 and 88:
(23) Goodwill EUR Million Total Gro
Page 89 and 90:
Finance leases EUR Million Lands an
Page 91 and 92:
The balance consists of provisions
Page 93 and 94:
The fair value of plan assets evolv
Page 95 and 96:
Historical development of defined b
Page 97 and 98:
Analysis of total financial debt by
Page 99 and 100:
The choice of borrowing currency de
Page 101 and 102:
The “Pledges given or irrevocably
Page 103 and 104:
Mitigation efforts The potential im
Page 105 and 106:
In respect of political risks, Solv
Page 107 and 108:
Management by projects, with a conc
Page 109 and 110:
2006 Consolidation Scope The Group
Page 111 and 112:
List of fully consolidated Group co
Page 113 and 114:
GREAT BRITAIN Fournier Pharmaceutic
Page 115 and 116:
List of proportionately consolidate
Page 117 and 118:
SOUTH KOREA Inergy Automotive Syste
Page 119 and 120:
Income statement of Solvay S.A. (su
Page 121 and 122:
Additional comment The preparation
Page 123 and 124:
Report on the application of the Co
Page 125 and 126:
Introduction This report presents t
Page 127 and 128:
example, a hostile public takeover
Page 129 and 130:
send either their notification of p
Page 131 and 132:
Year of birth Year of 1st appointme
Page 133 and 134:
with the Solvay group, for example
Page 135 and 136:
of the Finance Committee: EUR 2 500
Page 137 and 138:
for decision-making. He makes sure
Page 139 and 140:
derivative instruments) before the
Page 141 and 142:
The Solvay share compared with the
Page 143 and 144:
control systems work. 5. Minutes As
Page 145 and 146:
“… I have always sought to serv
Page 147 and 148:
3 Executive Committee and General M
Page 149 and 150:
Shareholders’ diary - May 8, 2007
show all

+8 - Solvay

Create successful ePaper yourself

Delete template?

Save as template?